BioCentury | Jun 30, 2020
Product Development

Second death in Audentes gene therapy trial may highlight need for more careful dosing

...Ultragenyx was tested in a dose-finding Phase I/II trial at up to 1 x10 13 gc/kg...
BioCentury | Jun 26, 2020
Emerging Company Profile

Artiva launches with $78M to develop Korean biotech’s NK cell programs outside Asia

...up Artiva, bringing to San Diego allogeneic natural killer cell technology from South Korean company GC...
...well as an initial pipeline, from Green Cross LabCell Corp. (KOSDAQ:144510). Artiva’s launch sprang from GC...
...cellular immunotherapy companies. A banker who Farrell had worked with before introduced the CEO to GC...
BioCentury | May 16, 2020
Product Development

Daily Chart: ide-cel’s challengers in the BCMA pipeline

Wednesday’s refusal-to-file letter for idecabtagene vicleucel slows the cell therapy from bluebird bio Inc. and Bristol Myers Squibb Co. in the race to market a product targeting BCMA to treat multiple myeloma (see “Refusal-to-File Letter...
BioCentury | May 8, 2020
Product Development

Japanese approval for Gilead’s remdesivir

...co-leading the alliance, which welcomed four new members Thursday: ADMA Biologics Inc. (NASDAQ:ADMA), BioPharma Plasma, GC...
BioCentury | Apr 25, 2020
Product Development

AACR Primer: first virtual AACR meeting of year will include data from over 40 trials

Data from an allogeneic CAR T therapy, bispecific mAbs and new immuno-oncology combinations are some of the highlights expected at the first virtual meeting of the year for the American Association for Cancer Research. Due...
BioCentury | Feb 19, 2020
Finance

Eyeing IPO, Canbridge raises $98M to advance, commercialize products

Canbridge raised $98 million in a series D round to build out its commercial infrastructure in anticipation of two potential NDA approvals in mainland China this year. Canbridge also intends to solidify its rare disease...
BioCentury | Nov 7, 2019
Financial News

More weakness among IPOs as Galera, Centogene limp into marketplace

Cancer company Galera became the latest biotech whose NASDAQ IPO fell short of expectations, while shares of diagnostics company Centogene dipped after pricing its offering at the low end of its proposed range. A third...
BioCentury | Oct 16, 2019
Financial News

Oct. 15 Financial Quick Takes: Phathom, Galera, J&J earnings, RTW Investments, Azitra, MaveriX

Phathom, Galera move toward listings Phathom Pharmaceuticals Inc. proposed terms for an IPO on NASDAQ. The GI company proposed to sell 7.9 million shares at $18-$20; at the mid-point, it would raise $150.1 million at...
BioCentury | Jul 18, 2019
Emerging Company Profile

DNA Script: enzymatic DNA synthesis

...high GC content -- the percentage of G and C bases in DNA -- problematic, "GC...
BioCentury | Jun 22, 2019
Clinical News

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

Cotellic/Tecentriq combo misses in melanoma Exelixis Inc. (NASDAQ:EXEL) revealed in a Thursday SEC filing that Cotellic cobimetinib plus Tecentriq atezolizumab from partner Genentech Inc. missed the primary endpoint of improving progression-free survival vs. Keytruda pembrolizumab...
Items per page:
1 - 10 of 135